FindTrial
Sign In

PPI as an adjunct to endoscopic hemostasis for bleeding peptic ulcer a randomized clinical trial of a high vs a standard regimen for the i.v. drug infusion - PPI for bleeding peptic ulcers

PPI as an adjunct to endoscopic hemostasis for bleeding peptic ulcer a randomized clinical trial of a high vs a standard regimen for the i.v. drug infusion - PPI for bleeding peptic ulcers

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2006-005454-76-IT
Enrollment
Unknown
Registered
2006-12-04
Start date
2004-10-01
Completion date
Unknown
Last updated
2012-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with peptic ulcer bleeding MedDRA version: 8.1 Level: LLT Classification code 10034344 Term: Peptic ulcer haemorrhage

Interventions

Trade Name: OMEPRAZEN Pharmaceutical Form: Powder for infusion* Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 80-

Sponsors

IRCCS CASA SOLLIEVO DELLA SOFFERENZA
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Active peptic ulcer bleeding following a successful endoscopic hemostasis Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Peptic ulcers which have stopped to bleed spontaneously

Design outcomes

Primary

MeasureTime frame
Main Objective: To compare the efficacy of a high vs a standard regimen for the i.v. infusion of PPI;Secondary Objective: None;Primary end point(s): Evaluation of chimical efficacy of the two PPI regimens in team of re-bleeding and mortality rates following the index bleeding—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026